Havrix (Hepatitis A Virus (Inactivated), Algeldrate)

Havrix is indicated for active immunization against hepatitis A virus in individuals who are at risk of infection or who seek protection.

• Adults and children aged 12 months and older who have not been previously vaccinated.
• Travelers to regions where hepatitis A is endemic or outbreaks occur.
• Persons with occupational exposure to hepatitis A, such as laboratory workers.
• Individuals with chronic liver disease who need additional protection.
• Outbreak control measures in community settings.

Side effects reported after Havrix vaccination are generally mild to moderate and resolve without intervention.

Common

• Pain, redness, or swelling at the injection site.
• Low-grade fever or chills.
• Headache or fatigue.
• Mild muscle aches.
• Nausea or loss of appetite.

Serious

• Severe allergic reactions (anaphylaxis) requiring emergency care.
• Neurological events such as Guillain‑Barré syndrome, though rare.
• Persistent high fever lasting more than 48 hours.
• Severe joint pain or swelling.
• Signs of infection at the injection site that do not improve.

Healthcare providers should assess individual risk factors before administering Havrix.

• Verify that the patient has no known severe allergy to any vaccine component, including algeldrate.
• Defer vaccination in persons with acute moderate or severe illness until recovery.
• Counsel pregnant or breastfeeding individuals that safety data are limited; use only if benefits outweigh potential risks.
• Monitor for immediate hypersensitivity reactions for at least 15 minutes post‑injection.
• Document any prior hepatitis A vaccination to avoid unnecessary repeat dosing.
• Consider postponing vaccination in immunocompromised patients until immune status is stable.

While Havrix does not have many documented drug interactions, certain considerations are advised.

Avoid

• Concurrent administration of other live vaccines within four weeks, as it may affect immune response.
• Use of systemic corticosteroids at high doses that could suppress vaccine efficacy.

Use with caution

• Immunosuppressive therapies (e.g., chemotherapy, biologics) that may reduce antibody production.
• Antipyretics or analgesics taken prophylactically; they may mask mild post‑vaccination symptoms.
• Blood products or immunoglobulins given within two weeks, which could interfere with vaccine-induced immunity.
• Chronic alcohol use, which may impair immune response to vaccination.